Sanofi
As of Oct 22, 2026, Sanofi is in Stage 4, the downtrend phase, now in week 4 (since Sep 30, 2026). It closed at $41.96, 15.4% below its 52-week high and below its 200-day average, which is falling.
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is SNY early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
SNY among Drug Manufacturers - General14th of 21 by relative strength
All 21 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | MRK | Stage 2 · wk 16 | 92 | −0.6% |
| 2 | BIIB | Stage 2 · wk 21 | 92 | +11.6% |
| 3 | LLY | Stage 2 · wk 1 | 90 | +13.5% |
| 4 | AMGN | Stage 2 · wk 16 | 87 | +10.1% |
| 5 | OGN | Stage 2 · wk 23 | 87 | +0.1% |
| 6 | BMY | Stage 3 · wk 1 | 85 | +4.1% |
| 7 | JNJ | Stage 2 · wk 16 | 83 | −0.6% |
| 8 | PFE | Stage 2 · wk 8 | 77 | +7.9% |
| …14 | SNY | Stage 4 · wk 4 | 46 | +0.7% |
Sanofi: quick answers
What stage is Sanofi in?
As of Oct 22, 2026, Sanofi (SNY) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 30, 2026 and is in week 4. What the four stages mean
Is Sanofi in an uptrend?
No. Sanofi is in a Stage 4 downtrend. It trades 3.6% below its 200-day average, which is falling.
How far is Sanofi from its 52-week high?
Sanofi closed at $41.96 on Oct 22, 2026, 15.4% below its 52-week high of $49.59. Its 52-week low is $39.12.
How has Sanofi performed over the past year?
As of Oct 22, 2026, Sanofi is down 10.8% over the past year and down 8.2% so far in 2026.
Which sector and industry is Sanofi in?
Sanofi is in the Drug Manufacturers - General industry, part of the Health Care sector.
About this companyHealth Care· Drug Manufacturers - General
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab; and antibody collaboration with Regeneron Pharmaceuticals, Inc. to develop antibodies, such as Dupixent (dupilumab) as treatment for diseases driven by type 2 inflammation. manufacturing facility in Germany. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.